Survival impact of capsule status in stage I ovarian mucinous carcinoma—A mulicentric retrospective study

• Published in: European journal of obstetrics & gynecology and reproductive biology 2019-03, Vol.234, p.131-136
• Main Authors: Kajiyama, Hiroaki, Suzuki, Shiro, Yoshikawa, Nobuhisa, Kawai, Michiyasu, Nagasaka, Tetsuro, Kikkawa, Fumitaka
• Format: Article
• Language: English
• Subjects: Capsule status; Epithelial ovarian carcinoma; Mucinous carcinoma; Overall survival; Recurrence-free survival
• ISSN: 0301-2115; 1872-7654
• DOI: 10.1016/j.ejogrb.2019.01.009

The influence of capsule rupture on patients’ oncologic outcome has been controversial in early-stage ovarian carcinoma. The aim of this study was to investigate the significance of the capsule status in early-stage patients with mucinous epithelial ovarian carcinoma (mEOC). During the period of 1990–2015, 351 patients with stage I-IV mEOC were identified in the multicentric database. Of these, a total of 194 mEOC patients with a stage I tumor were in the study. The median follow-up of the surviving patients was 67.6 (2.0–248.1) months. The FIGO stage distribution was IA in 85 (43.8%), IB in 2 (1.0%), IC1 in 58 (29.9%), IC2 in 18 (9.3%), and IC3 in 31 (16.0%). The 5-year overall survival (OS) rates in patients with stage IA-B, IC1, and IC2-3 tumors were 95.8, 82.5, and 82.9%, respectively {IA-B vs. IC1: P = 0.0031, IA vs. IC2-3: P = 0.0042}. Similarly, the 5-year recurrence-free survival rates in patients with stage IA-B, IC1, and IC2-3 tumors were 93.5, 73.0, and 79.2%, respectively (Log-rank: P = 0.0034). Among all patients, 104 received adjuvant chemotherapy and 90 did not. There was no significant difference in each substage group between the non-chemotherapy and chemotherapy groups in the 5-year overall survival rate {chemotherapy (yes vs. no): 87.0 vs. 90.3%: P = 0.5389}. Multivariate analysis demonstrated that the capsule status was a significant prognostic factor for OS {IA-B (referent) vs. IC1: HR (95% CI): 3.527 (1.125–12.568), P = 0.0300)}. mEOC patients staged greater than IC1 show a marked risk of mortality even after postoperative chemotherapy.